Entheon Biomedical (XCNQ:ENBI) FCF Margin % : 0.00% (As of Feb. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Entheon Biomedical's Free Cash Flow for the three months ended in Feb. 2024 was C$-0.10 Mil. Entheon Biomedical's Revenue for the three months ended in Feb. 2024 was C$0.00 Mil. Therefore, Entheon Biomedical's FCF Margin % for the quarter that ended in Feb. 2024 was 0.00%.

As of today, Entheon Biomedical's current FCF Yield % is -20.01%.

The historical rank and industry rank for Entheon Biomedical's FCF Margin % or its related term are showing as below:

XCNQ:ENBI' s FCF Margin % Range Over the Past 10 Years
Min: -1028.95 Med: -586.48 Max: -144
Current: -204.62

During the past 7 years, the highest FCF Margin % of Entheon Biomedical was -144.00%. The lowest was -1028.95%. And the median was -586.48%.

XCNQ:ENBI's FCF Margin % is ranked worse than
54.59% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs XCNQ:ENBI: -204.62

Entheon Biomedical FCF Margin % Historical Data

The historical data trend for Entheon Biomedical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical FCF Margin % Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

FCF Margin %

Get a 7-Day Free Trial

-1,028.95

-144.00

Entheon Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
FCF Margin %	Get a 7-Day Free Trial															-157.50	-9.23	-	-	-

Competitive Comparison of Entheon Biomedical's FCF Margin %

For the Biotechnology subindustry, Entheon Biomedical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entheon Biomedical's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's FCF Margin % falls into.

Entheon Biomedical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Entheon Biomedical's FCF Margin for the fiscal year that ended in Nov. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Nov. 2023 )	/	Revenue (A: Nov. 2023 )
	=	-0.36	/	0.25
	=	-144.00 %

Entheon Biomedical's FCF Margin for the quarter that ended in Feb. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-0.095	/	0
	=	%

Entheon Biomedical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines